Agarwal Arun, Agarwal Aakanksha
Senior Consultant and Head, Department of Internal Medicine, Narayana Multispeciality Hospital, Jaipur, Rajasthan.
Intern, BJ Medical College, Ahmedabad, Gujarat.
J Assoc Physicians India. 2016 Oct;64(10):44-50.
Hemophagocytic lymphohistiocytosis (HLH) is a rare, underdiagnosed, fatal and devastating hyperinflammatory syndrome that has gained increasing recognition over the past decade. Patients with HLH present with clinical and laboratory evidence of uncontrolled inflammation. Delay in diagnosis and management inevitably leads to a rapidly progressive and fatal course. In this case series, we present 7 cases of secondary HLH (sHLH) in adults with their presentation, course, and outcomes.
We retrospectively looked at the 7 cases of secondary HLH who were diagnosed and managed in our institute between January 2013 and august 2015. Medical records were retrieved from medical records department and data analyzed and tabulated. The median age at diagnosis was 35 years (age range 26-72 years). Diagnosis was based on HLH 2004 diagnostic criteria.
We report profile of 7 adult patients with sHLH. All patients had a short history of illness (<2 weeks) and presented uniformly with prolonged fever, bi or trilineage cytopenia and multiorgan dysfunction syndrome (MODS) at admission or developed MODS during the course of their illness. None of them had prediagnosed HLH. All patients fulfilled 5 to 6 of 8 criteria as per HLH 2014 diagnostic criteria. The median length of hospital stay was 12 days (range 7-50 days) and the median time to diagnosis was 5 days (range 3 to 21 days). Mortality was 57%.
HLH is a rare and under-diagnosed clinical syndrome and is rapidly fatal if not diagnosed and managed timely. The cases reported in literature probably represent a tip of an iceberg of large number of undiagnosed cases mostly labeled as sepsis with MODS in critical care units. sHLH should be suspected in any patient who present with persistent and prolonged fever, transaminitis, cytopenia, and high serum Ferritin or dramatically rising serial serum Ferritin. Early diagnosis and prompt aggressive treatment are vital for patients' survival and favorable outcome.
噬血细胞性淋巴组织细胞增生症(HLH)是一种罕见、易漏诊、致命且极具破坏性的高炎症综合征,在过去十年中受到越来越多的关注。HLH患者具有炎症失控的临床和实验室证据。诊断和治疗的延迟不可避免地导致病情迅速进展并走向致命结局。在本病例系列中,我们报告了7例成人继发性HLH(sHLH)患者的临床表现、病程及转归。
我们回顾性分析了2013年1月至2015年8月在我院诊断和治疗的7例继发性HLH患者。从病历科调取病历记录,并对数据进行分析和列表。诊断时的中位年龄为35岁(年龄范围26 - 72岁)。诊断依据HLH 2004诊断标准。
我们报告了7例成人sHLH患者的情况。所有患者病程较短(<2周),入院时均表现为持续发热、两系或三系血细胞减少以及多器官功能障碍综合征(MODS),或在病程中出现MODS。他们均未在诊断前被诊断为HLH。根据HLH 2014诊断标准,所有患者均符合8项标准中的5至6项。中位住院时间为12天(范围7 - 50天),中位诊断时间为5天(范围3至21天)。死亡率为57%。
HLH是一种罕见且易漏诊的临床综合征,若不及时诊断和治疗,会迅速致命。文献报道的病例可能只是大量未确诊病例的冰山一角,这些病例在重症监护病房大多被诊断为伴有MODS的脓毒症。对于任何出现持续和长时间发热、转氨酶升高、血细胞减少以及高血清铁蛋白或血清铁蛋白急剧上升的患者,都应怀疑sHLH。早期诊断和及时积极治疗对患者的生存和良好转归至关重要。